NASDAQ: ABVXAbivax Sa Stock
$7.37-0.01 (-0.14%)
Updated Mar 24, 2025
ABVX Price
$7.37
Fair Value Price
-$2.69
Market Cap
$466.87M
52 Week Low
$5.50
52 Week High
$16.63
P/E
-2.42x
P/B
10.58x
P/S
35.59x
PEG
N/A
Dividend Yield
N/A
Revenue
$13.53M
Earnings
-$183.59M
Gross Margin
100%
Operating Margin
-1,279.23%
Profit Margin
-1,415.7%
Debt to Equity
4.06
Operating Cash Flow
-$160M
Beta
0.73
Next Earnings
Mar 31, 2025
Ex-Dividend
N/A
Next Dividend
N/A
ABVX Overview
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ABVX's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -9.02% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ABVX
Ranked#421 of 482
Ranked#421 of 482
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.60 | A | |
| $142.02 | A | |
| $7.60 | A |
Be the first to know about important ABVX news, forecast changes, insider trades & much more!
ABVX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ABVX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ABVX ($7.37) is overvalued by 374.02% relative to our estimate of its Fair Value price of -$2.69 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ABVX ($7.37) is not significantly undervalued (374.02%) relative to our estimate of its Fair Value price of -$2.69 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ABVX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ABVX due diligence checks available for Premium users.
Valuation
ABVX fair value
Fair Value of ABVX stock based on Discounted Cash Flow (DCF)
Price
$7.37
Fair Value
-$2.69
Undervalued by
374.02%
ABVX ($7.37) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ABVX ($7.37) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ABVX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ABVX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.42x
Industry
-118.78x
Market
32.57x
ABVX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
10.58x
Industry
4.72x
ABVX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ABVX's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
ABVX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ABVX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$213.8M
Liabilities
$171.5M
Debt to equity
4.06
ABVX's short-term assets ($185.51M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ABVX's short-term assets ($185.51M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ABVX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
ABVX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ABVX vs Biotech Stocks
Abivax Sa Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.